Dr. LOU Jing, was appointed as a Director on 5 September 2006 and was redesignated as an executive Director on 27 November 2014. He was appointed as the chairman of the Board on 1 April 2012. Dr. Lou is also the chief executive officer of the Company. He is responsible for the strategic development and planning, overall operational management and major decision making of the Group. He is a co-founder of the Group and joined Shenyang Sunshine Pharmaceutical Company Limited (“Shenyang Sunshine”) as a director of R&D in September 1995.

Dr. Lou also holds the following positions with other members of the Group:
1) director and chairman of the board of Collected Mind Limited (集思有限公司, “Collected Mind”);
2) director of Hongkong Sansheng;
3) director of Excel Partner Holdings Limited (特隆控股有限公司, “Excel Partner”);
4) director of Ample Harvest Investments Limited (溢丰投资有限公司, “Ample Harvest”);
5) director, chief executive officer and president of Shenyang Sunshine and chairman of the board of Shenyang Sunshine;
6) director and general manager of Liaoning Sunshine Bio-Pharmaceutical Company Limited (辽宁三生医药有限公司, “Liaoning Sunshine”);
7) director and chairman of the board of Taizhou Huan Sheng Investment Management Company Limited (泰州环晟投资管理有限公司, “Taizhou Huan Sheng Investment”);
8) executive director of Shenzhen Baishitong Technology Development Company Limited (深圳市百士通科技开发有限公司, “Shenzhen Baishitong”);
9) chairman of the board of Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd. (“Sciprogen”);
10) chairman of the board of Guangdong Sunshine Pharmaceutical Co., Ltd. (广东三生制药有限公司);
11) director and chairman of the board of NMV Desen Biotech Co., Ltd;
12) director of Gains Prestige Limited (泽威有限公司, “Gains Prestige”);
13) director of Strategic International Group Limited (“Strategic International”);
14) director and chairman of the board of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (“Sunshine Guojian”);
15) director and chairman of the board of Shanghai Xingsheng Pharmaceutical Company Limited (“Xing Sheng”);
16) executive director of Shanghai An Ran Biotech Co. Ltd.;
17) executive director of Sunshine Guojian Pharmaceuticals (Suzhou) Co. Ltd.;
18) director of Full Gain Pharmaceutical Limited;
19) director of Shanghai National Engineering Research Center of Antibody Medicine Co. Ltd.;
20) chairman of the board of Xinyisheng (Hainan) Commercial Factoring Co., Ltd.;
21) director of 3SBio (Hongkong) Limited;

Dr. Lou has been highly active in pharmaceutical research and has made substantial contribution to the Group’s R&D of pharmaceutical products. Dr. Lou was the leading scientist and principal investigator in the Group’s successful development of EPIAO and TPIAO. He co-invented a “preparation process for recombinant human thrombopoietin” and a “method for improving the stability of polypeptides in human bodies and its application” in 2000 and 2001, respectively. He has published in a number of academic journals on microbiology and medicinal biotechnology. His research has been recognized with various awards. In 2006, he was awarded the “First Prize of Shenyang Science and Technology Progress Award” (沈阳市科学技术进步一等奖) for his research on recombinant human thrombopoietin. In 2007, he was awarded the “Third Prize of Liaoning Province Scientific and Technological Achievements” (辽宁省科学成果转化三等奖) for his contribution to the industrialization of production of recombinant human thrombopoietin. In 2017, he was awarded “Liaoning Province Outstanding Entrepreneur” and “Friendship Award of Liaoning Province”. In 2022, he received the 15th “Tan Jia Zhen Life Sciences Award” . Dr. Lou obtained a Bachelor of Medicine degree in clinical medicine from Shanghai Second Military Medical University in July 1985. He conducted post-doctoral research at the National Institutes of Health of the United States after obtaining a Ph.D. degree in molecular and cell biology from Fordham University in the United States in February 1994. He also obtained an Executive Master of Business Administration from China Europe International Business School (中欧国际工商学院) in September 2008.

Ms. SU Dongmei was appointed as a Director on 11 June 2012 and was re-designated as an executive Director on 27 November 2014. Ms. Su is also the Company’s senior vice president and the general manager of Shenyang Sunshine. She is responsible for strategic direction of the Group. Ms. Su joined Shenyang Sunshine as a scientist of the research and development department in January 1993, and served as a director of the R&D department from 1997 to 2006. She subsequently served as the chief technology officer responsible for R&D and manufacturing process engineering of Shenyang Sunshine from 2006 to 2008. Ms. Su was promoted to vice president of Shenyang Sunshine in April 2008. Ms. Su served as a director of Shenyang Sunshine from August 2007 to June 2013, and was re-appointed on 18 July 2016. She also served as a director of Hongkong Sansheng from November 2009 to November 2014.

Ms. Su also holds the following positions with other members of the Group: (i) senior vice president and general manager of Shenyang Sunshine; (ii) supervisor of Liaoning Sunshine; (iii) director of Sciprogen; (iv) director of Guangdong Sunshine;  (v) director of Strategic International; (vi)executive director of Shenyang Jiasheng Agriculture Technology Co., Ltd.; (vii) director of Sunshine Guojian; (viii) executive director of Shanghai Bo Ai Ke Biotech Co. Ltd.; (ix) trustee of Shanghai Sunshine Guojian Biotech Research Institute.

Ms. Su obtained a Bachelor’s degree in Biochemistry from Jilin University (吉林大學) in July 1992 and a Master’s and a Doctorate degree in Microbiology and Pharmacology from Shenyang Pharmaceutical University (瀋陽藥科大學) in June 2001 and July 2010, respectively. She has published in a number of academic journals on microbiology and medicinal biotechnology.

Mr. HUANG Bin was first appointed as a Director on 5 September 2006 and ceased to be a Director on 29 May 2013. Mr. Huang was re-appointed as an executive Director on 27 November 2014, and was re-designated as a non-executive Director on 20 June 2019. Mr. Huang joined Shenyang Sunshine in 1993 as a manager of the human resources department.

Mr. Huang also holds the following positions (in a non-executive capacity) with other members of the Group: (i) director and vice president of Shenyang Sunshine; and (ii) director and general manager of Taizhou Huan Sheng Investment.

Mr. Huang received a diploma in Engineering from Northeast University (東北大學) in July 1987. He attended a one-year training program in business management in Tsinghua University (清華大學) from April 2000 to April 2001.

Mr. PU Tianruo was appointed as an independent non-executive Director on 23 May 2015, with such appointment taking effect on 1 June 2015. Previously, he served as an independent Director and the audit committee chair of the Company from 1 September 2012 to 29 May 2013.

Mr. Pu has substantial experience in accounting and finance. He serves as an independent non-executive director of several companies, including Autohome Inc. (NYSE: ATHM; HKEx: 2518) since December 2016, One Connect Financial Technology (NYSE: OCFT; HKEx:6638) since December 2019, and AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) since October 2022. Mr. Pu was previously an independent non-executive director of the following public companies: Renren Inc. (NYSE: RENN), Kaixin Auto (NASDAQ: KXIN), Luckin Coffee (previously NASDAQ: LK). He was previously the chief financial officer of Zhaopin Ltd. (previously NYSE: ZPIN). Mr. Pu obtained a Bachelor’s degree in English Language from China Foreign Affairs University (外交學院) in July 1991, a Master of Science degree in Accounting from the University of Illinois, College of Business Administration in May 1996 and an MBA degree from Northwestern University Kellogg School of Management in the U.S. in June 2000.

Ms. YANG, Hoi Ti Heidi ( 楊 凱 蒂 ) was appointed as an independent non-executive Director on 29 June 2021. Ms. YANG has been the Global Managing Director, Asian and World Art at Christie’s Hong Kong Limited since January 2021 and had served as a member of the Listing Committee of the Stock Exchange from July 2019 to July 2021. Prior to joining Christie’s Hong Kong Limited, Ms. YANG had over 28 years of experience in the financial sector and had held the positions of Managing Director and Head of Corporate Advisory Group, Asia Pacific at Deutsche Bank Asia Limited, Managing Director and Head of Corporate Finance Group at UBS Investment Bank Asia, and Analyst, Associate and Vice President at Morgan Stanley Asia Limited. Ms. YANG holds a Bachelor of Arts degree majoring in economics from Columbia University, New York.

Mr. NG, Joo Yeow Gerry (黃祖耀) was appointed as an independent non-executive Director on 21 January 2022. He has substantial experience in corporate planning, business expansion and development as well as cross-border management, particular in the investment management business in the Asian region. Mr. Ng has been an Independent Non-executive Director of AIA Company (Trustee) Limited, a subsidiary of AIA Group Limited (HK Stock Code: 1299), since August 2021, for its pension fund business in Hong Kong. He had served as the Chief Executive Officer, Asia ex Japan of Baring Asset Management (Asia) Limited (“Baring Asset Management”) up to December 2019, having been appointed as Managing Director of Baring Asset Management in December 2004. During his time at Baring Asset Management, Mr. Ng managed and had oversight of different offices in the Asian region including those in Shanghai, Hong Kong, Taipei and Seoul, and was responsible for the business management of a substantial book of business in retail mutual funds and institutional client assets. Mr. Ng has also had ample and broad range of experience working with key sovereign wealth funds, large institutions and regulators in the region. Prior to joining Baring Asset Management, Mr. Ng was employed by JF Asset Management Limited (now JP Morgan Asset Management (Asia Pacific) Limited) from May 1992 to November 2004. During this period, he held various positions including Head of Asian Institutional Clients and Finance Director (JF Unit Trusts), and had focused on sales, business development and client servicing in the Asian region. Mr. Ng had also worked at Price Waterhouse (now PricewaterhouseCoopers) in both London and Hong Kong from September 1986 to April 1992 with his last role serving as an Audit Manager in the Hong Kong office.

Mr. Ng is a Senior Fellow of the Hong Kong Securities and Investment Institute and has also previously held many respectable and prestigious positions in different professional and regulatory bodies, including formerly being a Member of the Securities and Futures Appeals Tribunal, the Chairman and Executive Committee Member of Hong Kong Investment Funds Association, a Panel Member of the Mandatory Provident Fund Schemes Appeal Board, and a Member of Hong Kong Trade Development Council Financial Services Advisory Committee.

Mr. Ng holds a Bachelor of Science degree (with first class honours) majoring in civil engineering from Imperial College, London. He is also a Chartered Accountant (England and Wales) and Certified Public Accountant (Hong Kong).

Dr. Zhang Dan (張丹博士) was appointed as an independent non-executive Director on 30 December 2022. He has extensive experience in the field of medicine and pharmaceuticals, and has held numerous respectable and prestigious positions in the industry. Dr. Zhang served as the first Chairman of the board of directors (Greater China region) and the Vice-President of a U.S. company, Quintiles Transnational Corp.. Dr. Zhang had experience working at Sigma Tauresearch Inc., a U.S. company, during which he was in charge of the clinical development and safety evaluations of drugs in respect of the market in North America. In 2007, Dr. Zhang co-founded ClinChoice Inc. (昆翎醫藥) (formerly known as FMD China (方恩醫藥)), a clinical contract research organization (CRO) dedicated to the development of innovative medicines. He was the Chairman and CEO of this company from 2007 to 2019, and has been the Chief Strategy Officer and a director of this company since 2020. He has also served as (i) the Chief Scientist at Shenzhen Grandbaybio Development Consulting Co. Limited (深圳興灣生物醫藥發展顧問有限公司) since 2020; (ii) the co-chairman of the board of directors of Hong Ji Biotechnology (Beijing) Co. Limited ( 弘際生物科技( 北京) 有限責任公司) since 2021; and (iii) the co-chairman of the board of directors of Jiangsu Hillgene Medical Co. Limited ( 江蘇譜新生物醫藥有限公司 ) since 2022.

Dr. Zhang served as a consultant and a visiting professor at Peking Union Medical College and Harbin Medical University, respectively. Dr. Zhang has been a member of China Pharmaceutical Innovation and Research Development Association (PhIRDA) (中國醫藥創新促進會) from 2020 to 2022. He currently also serves as the head of the ICH E19 IFPMA expert committee and a ICH working group expert in the NMPA.

Dr. Zhang completed his pre-medical training at the Department of Biology at Peking University in 1984. He then studied Medicine at Peking Union Medical College from 1981 to 1989, and was subsequently awarded with a Doctor of Medicine by the State Council of the PRC government. He further obtained a Master of Public Health degree from Harvard University in 1990 and a Master of Science in Health Care Management degree in 1995 from the Wharton School of the University of Pennsylvania. He was also elected as a foreign member of the Russian Academy of Engineering in 2020.